Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.41 |
| ▸ | RAF1 | P04049 | 11/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26189260 | 0.85 | RAF1 (0.41) | MAPK14RAF1KDM4EALDH1A1LMNA | |
| SCHEMBL13906531 | 0.84 | RAF1 (0.45) | MAPK14RAF1KDM4EALDH1A1LMNA | |
| SCHEMBL3715482 | 0.83 | PTPN5 (0.38) | MAPT | |
| SCHEMBL4147003 | 0.82 | HPGD (0.42) | MAPK14RAF1KDM4EALDH1A1LMNA | |
| SCHEMBL21411362 | 0.81 | ALDH1A1 (0.58) | MAPK14RAF1KDM4EALDH1A1LMNA | |
| SCHEMBL14434356 | 0.81 | KDM4E (0.43) | MAPK14RAF1KDM4EALDH1A1LMNA | |
| SCHEMBL1406076 | 0.80 | MAPT (0.47) | MAPK14RAF1KDM4EALDH1A1LMNA | |
| SCHEMBL4168848 | 0.80 | MAPK14 (0.40) | MAPK14RAF1KDM4EALDH1A1LMNA | |
| SCHEMBL612156 | 0.79 | MAPT (0.42) | MAPK14RAF1KDM4EALDH1A1LMNA | |
| SCHEMBL101455 | 0.78 | RAF1 (0.42) | MAPK14RAF1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| EP-3533797-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-2540728-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20170209452-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-9655900-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-23 | — | — | US | disclosed |
| EP-2813509-B1 | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives | ASTRAZENECA AB (SE) | 2017-02-01 | — | — | EP | disclosed |
| EP-2813509-B1 | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives | ASTRAZENECA AB (SE) | 2017-02-01 | — | — | EP | disclosed |
| US-20160310494-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9388195-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-12 | — | — | US | disclosed |
| EP-2721036-B1 | NOVEL 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO[4,3-C]ISOQUINOLINE COMPOUNDS | TAKEDA GMBH (DE) | 2015-07-22 | — | — | EP | disclosed |
| EP-2298776-A1 | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
| EP-2150251-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | Amgen, Inc (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008137060-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1948665-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008002575-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299062-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007050726-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310494-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | MAPK14 1144/4885RAF1 825/4885KDM4E 1432/4885 |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | EGLN3, HIF1AN, EGLN2 | MAPK14 3427/4885RAF1 2596/4885KDM4E 873/4885 |
| US-20070299062-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC4R | MAPK14 2007/4885RAF1 4032/4885KDM4E 2926/4885 |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | MAPK14 1805/4885RAF1 3878/4885KDM4E 2607/4885 |
| US-20170209452-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | MAPK14 1144/4885RAF1 825/4885KDM4E 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.